No Man

Sign in

Join Free
Post RFQ

Anlotinib

TypeName: Business Offer

Category:

Offer Date:2019/09/04

Country: United States

Summary: Anlotibib is a multi-targetes kinase inhibitor of receptor tyrosine and could effectively resist the formation of new angiogenesis. It is undergoing a phase III clinical trial for therapy of metastatic or advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), and synovial sarcoma (SS). https://www.bocsci.com/anlotinib-cas-1058156-90-3-item-474328.html

Description:

OfferId: 5457

Name:Alex Brown

Telphone:

Email:[email protected]